Ausgabe 1/2019
Inhalt (12 Artikel)
State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development
Venkata Yellepeddi, Joseph Rower, Xiaoxi Liu, Shaun Kumar, Jahidur Rashid, Catherine M. T. Sherwin
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
Sophie E. Berends, Anne S. Strik, Mark Löwenberg, Geert R. D’Haens, Ron A. A. Mathôt
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Eva Germovsek, Charlotte I. S. Barker, Mike Sharland, Joseph F. Standing
Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
Sophida Boonsathorn, Iek Cheng, Frank Kloprogge, Carlos Alonso, Charmion Lee, Bilyana Doncheva, John Booth, Robert Chiesa, Adam Irwin, Joseph F. Standing
Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials
Rasmus Vestergaard Juul, Michael Højby Rasmussen, Henrik Agersø, Rune Viig Overgaard
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
Robert A. Hauser, Rajesh Pahwa, William A. Wargin, Cindy J. Souza-Prien, Natalie McClure, Reed Johnson, Jack T. Nguyen, Rajiv Patni, Gregory T. Went
Choosing the Allometric Exponent in Covariate Model Building
Jaydeep Sinha, Hesham S. Al-Sallami, Stephen B. Duffull
Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I
Jean-Marie Martinez, Aurélie Brunet, Fabrice Hurbin, A. Thomas DiCioccio, Clémence Rauch, David Fabre
Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II
Xavier Nicolas, Nassim Djebli, Clémence Rauch, Aurélie Brunet, Fabrice Hurbin, Jean-Marie Martinez, David Fabre
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
Sebastiaan C. Goulooze, Swantje Völler, Pyry A. J. Välitalo, Elisa A. M. Calvier, Leon Aarons, Elke H. J. Krekels, Catherijne A. J. Knibbe
Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Eva Germovsek, Charlotte I. S. Barker, Mike Sharland, Joseph F. Standing
Correction to: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
Sophida Boonsathorn, Iek Cheng, Frank Kloprogge, Carlos Alonso, Charmion Lee, Bilyana Doncheva, John Booth, Robert Chiesa, Adam Irwin, Joseph F. Standing